For example, CLL patients with higher expression levels of PDE7B have a several-year shorter median time-to-treatment compared to patients with lower levels of PDE7B expression (Zhang et al., 2011). This evidence concerns the gene PDE7B and B-cell chronic lymphocytic leukemia.